NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

AI Briefing

• – NorthStrive Biosciences announces arrival of EL-32 working cell bank and begins manufacturing optimization for dual myostatin assets targeting muscle preservation with GLP-1 therapies in collaboration with Modulant Biosciences.
• – The company's dual myostatin assets aim to address muscle wasting conditions, including muscular dystrophy and sarcopenia.
• – NorthStrive Biosciences is working with Modulant Biosciences to develop therapies that combine myostatin inhibition with GLP-1 to preserve muscle mass and function.